The Effect of $n$-3 Fatty Acids on Glucose Homeostasis and Insulin Sensitivity

P. FLACHS$^1$, M. ROSSMEISL$^1$, J. KOPECKY$^1$

$^1$Department of Adipose Tissue Biology, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic

Received December 7, 2013
Accepted December 16, 2013

Summary

Type 2 diabetes (T2D) as well as cardiovascular disease (CVD) represent major complications of obesity and associated metabolic disorders (metabolic syndrome). This review focuses on the effects of long-chain $n$-3 polyunsaturated fatty acids (omega-3) on insulin sensitivity and glucose homeostasis, which are improved by omega-3 in many animal models of metabolic syndrome, but remain frequently unaffected in humans. Here we focus on: (i) mechanistic aspects of omega-3 action, reflecting also our experiments in dietary obese mice; and (ii) recent studies analysing omega-3’s effects in various categories of human subjects. Most animal experiments document beneficial effects of omega-3 on insulin sensitivity and glucose metabolism even under conditions of established obesity and insulin resistance. Besides positive results obtained in both cross-sectional and prospective cohort studies on healthy human populations, also some intervention studies in prediabetic subjects document amelioration of impaired glucose homeostasis by omega-3. However, the use of omega-3 to reduce a risk of new-onset diabetes in prediabetic subjects still remains to be further characterized. The results of a majority of clinical trials performed in T2D patients suggest that omega-3 have none or marginal effects on metabolic control, while effectively reducing hypertriglyceridemia in these patients. Despite most of the recent randomized clinical trials do not support the role of omega-3 in secondary prevention of CVD, this issue remains still controversial. Combined interventions using omega-3 and antidiabetic or hypolipidemic drugs should be further explored and considered for treatment of patients with T2D and other diseases.

Key words

Diabetes • Obesity • Inflammation • Metabolic syndrome • Omega-3 fatty acids

Corresponding author

J. Kopecky, Department of Adipose Tissue Biology, Institute of Physiology of the Academy of Sciences of the Czech Republic, v.v.i., Vidoňska 1083, 14220 Prague 4, Czech Republic. Fax: +420 241 062 599. E-mail: kopecky@biomed.cas.cz

Introduction

Type 2 diabetes (T2D) as well as cardiovascular disease (CVD) represent major complications of obesity and associated metabolic disorders, which are clustered in the metabolic syndrome (including namely dyslipidemia, impaired insulin sensitivity and hypertension). The fundamental problem in the prevention and treatment of T2D is a maintenance and restoration of insulin sensitivity in target tissues, which is disturbed already in prediabetic subjects. Optimal strategies in the prevention of obesity and T2D are always based on a healthy lifestyle, including increased physical activity and proper nutrition. These manipulations were sufficient to lower the incidence of T2D in patients with impaired glucose tolerance (IGT) by 60 % (Tuomilehto et al. 2001, Knowler et al. 2002).

Long-chain polyunsaturated fatty acids (FA) of $n$-3 series (omega-3), which are abundant in marine fish, namely docosahexaenoic acid (DHA, 22:6n-3), eicosapentaenoic acid (EPA, 20:5n-3), and
docosapentaenoic acid (DPA, 22:5n-3); for the nomenclature, see Table 1), act as natural hypolipidemic and anti-inflammatory agents and ameliorate various aspects of the metabolic syndrome (reviewed in Flachs et al. 2009, Mozaffarian et al. 2013). However, while omega-3 affect different components of the syndrome to various extent, their effects are dose-dependent and involve complex mechanisms of action (Table 2 and below).

Table 1. Nomenclature of omega-3.

<table>
<thead>
<tr>
<th>Names</th>
<th>Chemical</th>
<th>Carboxyl-reference</th>
<th>Omega-reference</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linolenic acid</td>
<td>9,12,15-octadecenoic acid</td>
<td>18:3 Δ9 12 15</td>
<td>18:3 n-3</td>
<td>ALA</td>
</tr>
<tr>
<td>Eicosapentaenoic acid</td>
<td>5,8,11,14,17-eicosapentaenoic acid</td>
<td>20:5 Δ5 8 11 14 17</td>
<td>20:5 n-3</td>
<td>EPA</td>
</tr>
<tr>
<td>Docosapentaenoic acid</td>
<td>7,10,13,16,19-docosapentaenoic acid</td>
<td>22:5 Δ7 10 13 16 19</td>
<td>22:5 n-3</td>
<td>DPA</td>
</tr>
<tr>
<td>Docosahexaenoic acid</td>
<td>4,8,12,15,19-docosahexaenoic acid</td>
<td>22:6 Δ4 8 12 15 19</td>
<td>22:6 n-3</td>
<td>DHA</td>
</tr>
</tbody>
</table>

We focus here on the controversial topic related to the beneficial effects of omega-3 on insulin sensitivity and glucose homeostasis, which are documented in many animal models of metabolic syndrome, but less frequently observed in humans. The subject of this review has been covered in several articles in the past (Friedberg et al. 1998, Montori et al. 2000, Delarue et al. 2004, Lombardo and Chicco 2006), however a synopsis of a more recent knowledge is missing. We focus here on (a) mechanistic aspects of omega-3 action, reflecting also our studies in dietary obese mice; (b) recent studies regarding omega-3 effects in humans; and (c) possible reasons underlying the contrasting results in the animal and human studies.

Metabolism of essential fatty acids

Mammals cannot synthesize FA of n-6 and n-3 series, which contain double-bonds at C-6 and C-3 from the methyl end of the molecule, respectively. Polyunsaturated FA are exclusively synthesized by cells of plant origin. The most plentiful source of n-3 polyunsaturated fatty acid is marine phytoplankton, a major component of marine food chain. Precursors for the synthesis of long-chain polyunsaturated FA of n-6 series (omega-6) and omega-3 in mammals are linoleic acid (LA, 18:2n-6) and α-linolenic acid (ALA; 18:3n-3), respectively. Although LA and ALA give rise to different metabolites, the enzymes that participate in the formation of those metabolites are the same. In fact, LA and ALA compete for the enzyme Δ6 desaturase that is the first metabolic step necessary for their further conversion. Excessive amount of LA slows down the formation of EPA and DHA (i.e. omega-3). Even without this inhibitory effect the synthesis of EPA and DHA from their precursor ALA proceeds relatively slowly, therefore increased intake of EPA and DHA could have an effect even if the content of ALA in the diet is relatively high. EPA a DHA are interconvertable (Smith 2005). An excess of ALA inhibits LA metabolism, in particular the synthesis of arachidonic acid (AA; 20:4n-6; reviewed in Flachs et al. 2009). Omega-3 and omega-6 represent the fundamental components of phospholipids in cellular membranes and surface layer of intracellular lipid droplets. Polyunsaturated FA are usually located at the sn-2 position, while saturated or monounsaturated FA are bound to sn-1 position of the phospholipid molecules. Many effects of omega-3 and omega-6 depend on the formation of their active metabolites, oxylipins (the oxidation products – prostaglandins, leukotriens, protectins, etc.) and other lipid mediators (N-acylethanolamines, endocannabinoids, etc.). These molecules are generated from membrane phospholipids and act in both autocrine and paracrine manners (reviewed in Flachs et al. 2009, Hansen and Diep 2009, Wang and Ueda 2009, Rossmeisl et al. 2012, Flachs et al. 2013). The synthesis of oxylipins mostly depends on the activity of cyclooxygenase (type 1 and 2), for which AA is a „better“ substrate than EPA, and the activity of lipoxygenase, whose preferences for AA and EPA are
opposite compared to cyclooxygenase (Smith 2005). AA and EPA compete for cyclooxygenase and both EPA and DHA directly inhibit the activity of this enzyme. Therefore, a relatively mild elevation of the omega-3 content significantly slows down the synthesis of eicosanoids from AA. Based on this mechanism, it is possible to explain many beneficial effects of omega-3, first of all the suppression of inflammation, blood clotting, tumour and fat cell proliferation, and also relieve of pain. The discovery of pro-resolving and anti-inflammatory omega-3-derived lipid mediators called resolvins (E-resolvins and D-resolvins), protectins and maresins opened a new field concerning the active mechanisms involved in resolution of inflammation (Serhan and Petasis 2011). Similarly, N-acylethanolamines EPEA and DHEA, which are derived from EPA and DHA respectively, have anti-inflammatory effects (Balvers et al. 2012). Everlasting increases in the amount of LA (i.e. omega-6) in human diet prevent favourable anti-inflammatory and metabolic effects of omega-3 and facilitate the accumulation of adipose tissue (Blasbalg et al. 2011, Alvheim et al. 2012; and see below). This is also the reason why beneficial effects of ALA (i.e. omega-3) become apparent when the diet is based on animal fats with a relatively low content of LA rather than on regular plant oils with higher LA content. If the diet contains high amounts of LA, then it is only a supplementation with EPA and DHA, but not with ALA, that leads to a favourable effect (Storlien et al. 1991).

Table 2. Effects of omega-3 on metabolic syndrome features and associated diseases in humans.

<table>
<thead>
<tr>
<th></th>
<th>Effect of omega-3</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy individuals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood pressure</td>
<td>No change or lowering</td>
<td>(Gustafsson et al. 1998, Lahoz et al. 1999)</td>
</tr>
<tr>
<td>Subjects with metabolic syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>Improvement reviewed in (Jeppesen et al. 2013)</td>
<td></td>
</tr>
<tr>
<td>Obesity</td>
<td>No change or marginal improvement*</td>
<td>(Warner et al. 1989, Mori et al. 1999, Krebs et al. 2006, Kunesova et al. 2006, Hill et al. 2007, Thordsdottir et al. 2007)</td>
</tr>
<tr>
<td>New-onset diabetes</td>
<td>Remains to be characterized</td>
<td></td>
</tr>
<tr>
<td>Patients with T2D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IGT and IR</td>
<td>No change or marginal improvement</td>
<td>(Pelikanova et al. 1993, Kesavulu et al. 2002, Bosch et al. 2012, Sarbolouki et al. 2013) and other</td>
</tr>
<tr>
<td>Patients with CVD</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Especially, in combination with calorie restriction or physical exercise. For details, see the main text.
Current guidelines of various societies regarding omega-3 the optimal intake in general population are reviewed in (Lorente-Cebrian et al. 2013). Specifically, the guidelines of the European Society of Cardiology and the European Association for the Study of Diabetes on the management of diabetes mellitus, prediabetes, and cardiovascular disease recommend consumption of two to three servings of fish (preferably oily) each week, corresponding to approximately 0.5 g EPA+DHA daily (Ryden et al. 2013).

Key mechanisms underlying deterioration of insulin sensitivity

Among the pathological states belonging to the metabolic syndrome, the strongest correlation exists between obesity and T2D (Kopelman 2000). This close link reflects several mechanisms, including: (a) impairment of insulin signaling in muscle and other tissues due to excessive accumulation of intracellular lipid products in obesity (lipotoxicity); (b) abnormal modifications of intracellular as well as extracellular proteins (such as glycated hemoglobin, HbA1c) caused by elevated levels of glucose (glucotoxicity); (c) increased production of pro-inflammatory adipokines in fat cells and endocrine and paracrine actions of these molecules.

Development of insulin resistance (IR) represents part of a vicious cycle including other metabolic disturbances, namely a compensatory increase in the production of insulin, which is required for the maintenance of glycemia in face of an impaired insulin sensitivity at the periphery, thus leading eventually to an insufficient secretion of insulin from „exhausted“ β-cells due to a lipotoxic and glucotoxic damage. T2D develops following a prolonged period of euglycemic IR, which progresses with the development of β-cells failure. Preceding disorders of glucose metabolism, impaired fasting glucose (IFG) and IGT, are referred to as prediabetes (for the diagnostic criteria of prediabetes and T2D, see Table 3). It is also associated with a low capacity to adapt fuel oxidation to fuel availability, i.e. impaired metabolic flexibility, the key factor in the development of T2D, which is preceding the onset of overt disease (Corpeleijn et al. 2008).

Systemic IR reflects mainly the impairment of insulin action in the skeletal muscle that contributes the most to whole-body glucose consumption and impaired metabolic flexibility, but also in the liver, the site of gluconeogenesis, storage of glycogen, and release of glucose into the circulation. However, in spite of a relatively small contribution of adipose tissue to whole-body glucose consumption, impaired glucose transport into fat cells leads to IR in the muscle and liver (Abel et al. 2001; and see below).

The mechanism of lipotoxic impairment of insulin signaling is not understood in full. Circulating FA can activate cell-signaling pathways, which interfere with insulin action (reviewed in Glass and Olefsky 2012), while the accumulation of intracellular FA and other lipid products directly inhibits insulin signaling pathway and thus insulin-stimulated glucose transport (for review see Lowell and Shulman 2005). Better known are the mechanisms underlying the pathological storage of lipids in other tissues than adipose tissue (i.e. ectopic fat storage). These mechanisms include: (a) insufficient capacity of adipose tissue for the storage of FA due to hypertrophy of adipocytes in obesity or due to a pathological reduction of fat stores in lipodystrophy – i.e. insufficient expandability of adipose tissue (Virtue and Vidal-Puig 2010); as we have shown previously (Medrikova et al. 2011), adipose tissue expandability is higher in female as compared with male mice fed obesogenic high-fat (HF) diet, consistent with a lower risk of development of various adverse metabolic consequences of obesity in females than in males; and (b) insufficient oxidation of FA in muscle, most frequently as a result of low physical activity due to a lowering of

| Table 3. World Health Organization cut-points for diagnosing prediabetes and T2D. |
|--------------------------|--------------------------|
| **Diagnose/measurement** | **Recommended cut-points** |
| Prediabetes              |                          |
| **IFG**                  |                          |
| Fasting plasma glucose   | ≥6.1 mmol/l (≥110 mg/dl) |
| OGGT: 2-hour post-load plasma glucose | <7.8 mmol/l (<140 mg/dl) |
| **IGT**                  |                          |
| Fasting plasma glucose   | <7.0 mmol/l (<126 mg/dl) |
| OGGT: 2-hour post-load plasma glucose | ≥7.8 mmol/l (≥140 mg/dl) |
| Diabetes                 |                          |
| HbA1c                    | ≥6.5 % (48 mmol/mol)     |
| Fasting plasma glucose   | ≥7.0 mmol/l (≥126 mg/dl) |
| OGGT: 2-hour post-load plasma glucose | ≥11.1 mmol/l (≥200 mg/dl) |

Adapted from (Ryden et al. 2013).
mitochondrial oxidative capacity during ageing (Lowell and Shulman 2005) or due to a relative insufficiency in the face of lipid overload (Muioio and Neufier 2012).

Some adipokines (like adiponectin and leptin) increase insulin sensitivity in muscle by stimulating AMP-activated protein kinase (AMPK; Minokoshi et al. 2002, Yamauchi et al. 2002), i.e. the cellular energy sensor controlling metabolic fluxes in cells of many tissues. Elevated endocannabinoid tonus in obesity may inhibit AMPK and deteriorate its function (reviewed in Flachs et al. 2013). AMPK inhibits lipogenesis and stimulates oxidation of FA and transport of glucose into cells. AMPK is activated not only by adipokines, but also due to physical activity. Therefore, AMPK stimulates influx of glucose into muscle cells independently of insulin (Barnes and Zierath 2005). AMPK can be activated in response to metformin (Fryer et al. 2002), the common antidiabetic drug. Moreover, thiazolidinediones (TZD), used as insulin-sensitizers in the treatment of diabetic patients (e.g. pioglitazone), may stimulate AMPK activity in many tissues, rapidly and independently of PPARγ-mediated gene transcription (Lebrasseur et al. 2006; and see below).

**Physiological and cellular functions of omega-3 in the context of metabolic syndrome**

Biological effects of dietary omega-3 depend on their ability to be absorbed in the intestine and transported to systemic circulation and target tissues (i.e. bioavailability), which could largely differ among individuals and may depend on many factors, including stimulation of the release of pancreatic lipases in response to bulk of dietary lipids and the lipid form of their supplementation (reviewed in Schuchardt and Hahn 2013). For instance, omega-3 supplemented as fish oil (i.e. in the form of triacylglycerols (TAG) increased the percentage of DHA+EPA (of total FA) in red blood cell membranes (omega-3 index) more efficiently than omega-3 supplemented as ethyl-esters in healthy volunteers (Neubronner et al. 2011). Furthermore, when compared with fish oils, the bioavailability of dietary DHA and especially of EPA was even better when omega-3 were supplemented as marine phospholipids, as demonstrated both in mice (Rossmeisl et al. 2012) and in humans (Maki et al. 2009, Schuchardt et al. 2011, Ulven et al. 2011). Several comparative studies in obese rodent models have suggested that improved bioavailability of omega-3 also confer their increased metabolic efficiency. For instance, omega-3 PL either in the form of krill oil (Batetta et al. 2009) or isolated from fish meal (Rossmeisl et al. 2012) reduced hepatic steatosis and the levels of endocannabinoids 2-AG and AEA in abdominal white adipose tissue (WAT) more efficiently than fish oils. However, although the superior effects of omega-3 phospholipids have been linked primarily to improved DHA and/or EPA bioavailability (see above), it is still unclear whether there are also other mechanisms involved.

Reflecting all the differences in bioavailability of omega-3 (see above), it is becoming apparent that omega-3 index represents the best biomarker of omega-3 status and indicator of the biological effects of these lipids, especially in lowering the risk of CVD (Harris 2008, Schuchardt and Hahn 2013; and see below). Variability of omega-3 index in erythrocytes, where EPA and DHA are contained in membrane phospholipids, is lower as compared with omega-3 index in plasma phospholipids (contained in lipoproteins) or total plasma lipids, while especially total plasma lipid omega-3 index shows the biggest differences (~11 %) between fasted and fed state (Harris and Thomas 2010). This difference is only ~1 % and ~5 % in the case of omega-3 index in erythrocytes and plasma phospholipids, respectively (Harris and Thomas 2010). Nevertheless, even omega-3 index in fasted plasma phospholipids could serve as an excellent biomarker of omega-3 status while predicting the risk of CVD (Mozaffarian et al. 2013; and below). A large prospective study on ~2,700 adult humans demonstrated a non-linear relationship between the content of omega-3 in the diet and in plasma phospholipids, with a sharp increase in the plasma omega-3 levels up to 0.5 g EPA+DHA daily dietary intake, and then smaller increases in the systemic levels thereafter (Mozaffarian et al. 2013). Our results in mice, also consistent with findings in humans, indicated saturable incorporation of DHA into plasma lipids, while a linear relationship between dietary and plasma EPA levels was found (Rossmeisl et al. 2012). Furthermore, our study indicated differences in the dose-dependent accumulation of EPA and DHA in various tissues in mice (Kopecky et al. 2009).

Concerning diverse biological effects of omega-3, primarily their whole-body anti-inflammatory action should be considered, which is important with respect to low-grade inflammation associated with obesity and metabolic syndrome, and which is also tightly linked with the metabolic effects of omega-3 in the liver, adipose tissue and muscle, i.e. tissues contributing the most to the underlying pathophysiology
of IR and T2D. These mechanisms are being studied mostly in laboratory animals (see Fig. 1), while the extrapolation to humans is not straightforward.

**Effects of omega-3 in the liver**

Major mechanisms associated with the effects of omega-3 in the liver include (see also Fig. 1): (a) activation of PPARα, resulting in the increase of FA oxidation in both peroxisomes and to a lesser extent in mitochondria; (b) decrease of SREBP-1 gene expression, leading to the inhibition of lipogenic genes expression and lower formation of FA, TAG, and VLDL (Lombardo and Chicco 2006); (c) activation of AMPK in liver (Suchankova et al. 2005), probably through an adiponectin-mediated mechanism (Jelenik et al. 2010); and (d) higher production of anti-inflammatory omega-3-derived lipid mediators (resolvins E1 and D1 and protectin D1) that protect hepatocytes from oxidative stress and DNA damage during necroinflammatory liver injury (Gonzalez-Periz et al. 2009, Rius et al. 2012).

In rodents, activation of PPARα stimulates formation of peroxisomes much more than in humans (Delarue et al. 2004), reflecting the major differences in the PPARα signaling between the two species (Rakhshandehroo et al. 2009). Induction of peroxisomal rather than mitochondrial β-oxidation was shown to mediate the anti-obesity effect of omega-3 in rodents (Fiamoncini et al. 2013), which is consistent with a very weak or non-existent anti-obesity effect of omega-3 in humans (Mori et al. 1999, Skurnick-Minot et al. 2004, Kunesova et al. 2006; and see also Table 2). Stimulation of liver AMPK (see above) may augment metabolic effects of omega-3 based on the modulation of the activity of transcription factors PPARα and SREBP-1. As a result of all these changes, liver TAG content decreases and the sensitivity of hepatocytes to insulin increases. At the whole organism level, the metabolic effects of omega-3 in the liver contribute to a decreased VLDL-TAG secretion (Kuda et al. 2009). Reduced plasma levels of TAG is the most prominent effect of a dietary intake of EPA and DHA in humans (Balk et al. 2004). However, this could be also a result of different mechanisms, such as modulation of postprandial lipid metabolism.

**Effects of omega-3 in adipose tissue**

Omega-3 and the related oxylipins modulate gene expression through a variety of transcription factors and their effects are tissue-specific. In WAT, an important target is represented by peroxisome proliferator-activated receptor γ (PPARγ). This is a nuclear receptor acting as a ligand-dependent transcription factor. It binds not only lipid molecules (above), but also TZD (Kintscher and Law 2005). After binding the ligands, PPARγ stimulates expression of genes engaged in differentiation of fat cells, namely genes encoding FA transporters and lipogenic genes. In fat cells, also other members of the PPAR family could be activated by the above ligands, namely PPARα and PPARδ, resulting in the stimulation of FA oxidation in mitochondria and peroxisomes (Luquet et al. 2005, Madsen et al. 2005, Hensler et al. 2011). As we have shown in mice, omega-3 stimulate formation of mitochondria in fat cells (Flachs et al. 2005) and specifically in epididymal WAT in the abdomen (but not in subcutaneous fat) activate the expression of the gene for carnitine-palmitoyl-transferase 1 (Flachs et al. 2005), that stimulates the entry of FA into mitochondria; see Figure 1. In abdominal WAT, omega-3 also induced mitochondrial β-oxidation measured ex vivo either in tissue fragments or in isolated adipocytes (Flachs et al. 2005, 2011). An increase of FA oxidation in fat cells may contribute to anti-obesity effects of EPA and DHA, and also to the hypolipidemic effects of these molecules. The protective action of omega-3 against obesity in mice seems to be stronger in case of DHA than EPA and it results in part from the inhibition of fat cell proliferation (Ruzickova et al. 2004, Hensler et al. 2011). The metabolic component of the anti-obesity effect of omega-3, especially in the combination treatment with calorie restriction, reflects marked stimulation of lipid catabolism in WAT which can be explained by the activation of a futile substrate cycle based on lipolysis of intracellular TAG and FA re-esterification (TAG/FA cycle) (Flachs et al. 2013, Janovska et al. 2013). Importantly, these changes are linked to a suppression of low-grade inflammation in this tissue (Flachs et al. 2011). Both, the metabolic and anti-inflammatory effect of omega-3 in WAT largely depends on the formation of their active metabolites (Flachs et al. 2011, 2013) and the normalization of the tonus of the endocannabinoid system (Rossmeisl et al. 2012), and are probably modulated by AMPK (Kopecky et al. 2009). Furthermore, our results demonstrate that the anti-obesity effect of omega-3 is independent on uncoupling protein 1-induced thermogenesis (Flachs et al. 2013, Janovska et al. 2013; see Fig. 1).
Fig. 1. Tissue effects of omega-3 as revealed by studies on dietary obese mice. Proposed scheme of modulation of metabolic fluxes in WAT, liver, skeletal muscle and intestine is based mostly on our studies on mice fed an obesogenic corn-oil based HF diet (15, 59, and 26 % calories as protein, fat and carbohydrate, respectively) supplemented or not with omega-3 concentrate (replacement of 5 to 44 % of dietary lipids). The bioavailability and tissue accumulation of dietary DHA and especially of EPA were higher when omega-3 were supplemented as phospholipids instead of TAG. Appropriate studies are indicated by numbers: 1 – Flachs et al. 2006; 2 – Flachs et al. 2013; 3 – Janovska et al. 2012; 4 – Flachs et al. 2005; 5 – Rossmeisl et al. 2012; 6 – Jelenik et al. 2010; 7 – Rossmeisl et al. 2014; 8 – Horakova et al. 2012; 9 – van Schothorst et al. 2009; 10 – Kuda et al. 2007; 11 – Hensler et al. 2011; 12 – Hensler et al. 2011; * – our unpublished results; ** – intracolonic administration of omega-3 in mice resulted in enhanced GLP-1 secretion, substantial insulin release and subsequent reductions in glycemia (Morishita et al. 2008), our unpublished data suggest that omega-3 potentiate GLP-1 and insulin responses to a glucose load while normalizing abnormally elevated GIP levels observed in the HF diet-fed mice.; CB-1, cannabinoid receptors 1, decrease in the endocannabinoids tonus; mito/peroxi, mitochondrial/peroxisomal.

Also TZD stimulate formation of mitochondria in adipose tissue (Wilson-Fritch et al. 2004). However, in contrast to EPA and DHA, TZD also stimulate growth of adipose tissue. The growth of adipose tissue is associated with a formation of small adipocytes (Okuno et al. 1998). Because the small cells have a larger capacity for “trapping” FA as compared to large adipocytes, small adipocytes could serve as a “buffer” for lipids and in this way protect tissues against the lipotoxicity (Danforth 2000). The key role of WAT in glucose homeostasis is also supported by a finding of improved insulin sensitivity in mice with fat-specific over-expression of PPARγ (Sugii et al. 2009), which potentially involves changes in WAT distribution and fat cell size (see above), lowering of plasma non-esterified FA (NEFA) levels due to an activation of TAG/FA cycle in adipocytes (reviewed in Flachs et al. 2013), and stimulation of the FGF1-based mechanism (Jonker et al. 2012).

Omega-3, as well as TZD, modulate the secretion of adipokines from WAT. As shown in our laboratory (Flachs et al. 2006) and by others (Rossi et al. 2005, Neschen et al. 2006), EPA a DHA induce adiponectin in mice fed obesogenic diets, possibly via PPARγ acting directly upon the promoter of adiponectin gene (Iwaki et al. 2003). Moreover, preferential induction of adiponectin by the EPA/DHA concentrate in abdominal WAT was found (Flachs et al. 2006). While this induction of adiponectin by omega-3 was confirmed by some but not all human studies (Wu et al. 2013), it could contribute to the insulin-sensitizing effect of TZD. In contrast to adiponectin, plasma leptin levels were elevated dramatically in response to HF feeding, but
neither these nor leptin gene expression were affected by dietary EPA/DHA, supporting the idea that circulating leptin correlates with adiposity and glucose metabolism in adipocytes (Takahashi and Ide 2000).

In the fat cells, omega-3 also affect the expression of GLUT4 gene (Ruzickova et al. 2004) and glucose transport into the cells. In rodents, both GLUT4 expression and glucose transport are inhibited by a HF diet in parallel with the induction of IR, while admixing EPA and DHA to the diet has protective effects (Lombardo and Chicco 2006).

In addition, high anaplerosis in WAT mitochondria in obesity may result in insufficient oxidation of metabolites arising from degradation of branched-chain amino acids (BCAA), supporting further the development of systemic insulin resistance (Newgard et al. 2009, Adams 2011). TZD support BCAA catabolism in WAT (Hsiao et al. 2011), which may contribute significantly to the insulin-sensitizing effect of TZD in obesity (Newgard 2012). Our unpublished results suggest that also omega-3 could increase BCAA catabolism in WAT of mice (Fig. 1).

**Effects of omega-3 in skeletal muscle**

Preventive effects of EPA and DHA on the development of IR in muscles of rodents fed a HF diet correlate well with a decrease of muscle TAG content (Storlien et al. 1991). This most likely reflects the hypolipidemic effect of EPA and DHA, which results from a decrease in lipogenesis and increase of lipid oxidation in both liver and adipose tissue (see above). Adiponectin induced by EPA and DHA (and also by TZD) may stimulate AMPK in the muscle. In turn, AMPK augments oxidation of FA in myocytes and the influx of glucose into these cells (Yamauchi et al. 2002).

Omega-3 could affect muscle insulin sensitivity also via PPARγ-mediated mechanism in muscle cells. This is in agreement with a presence of IR in mice harbouring muscle-specific disruption of PPARγ (Hevener et al. 2003, Kintscher and Law 2005). Direct effects of omega-3 on tissue metabolism depend in large on the accumulation of these FA in phospholipids of cell membranes and modulation of oxylipin metabolism (Storlien et al. 1991; see above). Interestingly, the content of DHA in membrane phospholipids in human muscle also increased following a 4-week exercise (Helge et al. 2001).

Our results obtained in dietary obese mice indicate that the combined use of omega-3 and TZD exert synergistic beneficial effects in the prevention as well as reversal of IR (Kuda et al. 2009), while additively preserving metabolic flexibility to carbohydrates (Horakova et al. 2012; see Fig. 1). These effects reflected an improvement in skeletal muscle insulin sensitivity by the combined treatment, expressed as synergistic induction of glycogen synthesis at the basal and insulin stimulated conditions (Kuda et al. 2009). Moreover, metabolomic and gene expression analyses in skeletal muscle suggested complementary effects of the single interventions, with TZD augmenting insulin sensitivity by the modulation of BCAA metabolism, especially when combined with omega-3, and omega-3 supporting specifically mitochondrial oxidation of fatty acids. These metabolic effects were associated with the activation of a switch between glycolytic and oxidative muscle fibres and inhibition of low-grade tissue inflammation (Horakova et al. 2012).

**The effect of omega-3 on insulin sensitivity and obesity-associated disorders**

In the following text, animal and human studies will be commented separately, reflecting the fact, that the animal studies, while indispensable for understanding the mechanisms, have a clear limitation as far as the characterization of health benefits of omega-3 is concerned.

**Effects of omega-3 on insulin sensitivity in animal models**

Most studies carried out in animal models, mostly rodent species have focused on the development of IR, but relatively few have examined the effectiveness of these compounds in reversal of IR. Both prevention and reversal of IR have been studied in animals fed by the diet with a high content of either fat or carbohydrate, particularly sucrose or fructose (see below).

**Prevention of IR by omega-3 in dietary obese rodents**

HF diets induce accumulation of body fat and obesity, which is associated with alterations in insulin sensitivity, glucose intolerance, hyperinsulinemia and changes in lipid metabolism. In case of the effect of omega-3 on IR, it is the work of Storlien and colleagues (1987, 1991) that laid down the foundations of our current knowledge. These authors have shown that the replacement of only 6 % LA in the HF diet (in which plant oil was the only source of lipids and formed 59 %
of energy) for EPA and DHA protected the animals against the development of IR and limited the accumulation of adipose tissue. These effects are also reflected in lower plasma concentrations of TAG, NEFA and insulin (Lombardo and Chicco 2006).

Our studies on dietary obese mice fed a corn oil-based HF diet (Ruzickova et al. 2004, Flachs et al. 2006, Rossmeisl et al. 2012, Janovska et al. 2013) indicate that replacement of 5 to 44 % of dietary lipids by omega-3 in the form of either TAG or phospholipid can protect against the development of dyslipidemia, impaired glucose homeostasis and IR (see above). Furthermore, a series of our studies on the combined use of omega-3 with TZD (Kuda et al. 2009, Kus et al. 2011, Horakova et al. 2012, Rossmeisl et al. 2014) or calorie restriction (Flachs et al. 2011) clearly demonstrated that omega-3 markedly potentiate the beneficial effects of the combination treatments on insulin sensitivity, glucose tolerance, metabolic flexibility to carbohydrates, lipid metabolism and obesity (see above).

Concerning the link between abdominal fat accumulation and metabolic syndrome, it is important to stress that in HF diet-fed animals, omega-3 preferentially limit accumulation of gonadal and visceral WAT. This differential effect on fat depots is associated with changes in the expression of metabolic genes engaged especially in lipid metabolism and glucose uptake in adipocytes (Hun et al. 1999, Azain 2004, Ruzickova et al. 2004).

Rats fed high-carbohydrate (rich in sucrose or fructose) diets (HC) for a short period (3-6 weeks) develop hypertriglyceridemia, hyperinsulinemia, increased plasma NEFA levels and IR in peripheral tissues (Klimes et al. 1993). However, HC diet does not lead to an enhanced accumulation of fat despite the fact that other features of the metabolic syndrome are present. When omega-3 concentrate replaces the usual lipid constituent (oil) present in the HC diet, it prevents the onset of dyslipidemia and impaired glucose homeostasis. WAT, and in particular its insulin sensitivity, might play a crucial role in the omega-3’s effect (Huang et al. 1997, Peyron-Caso et al. 2002). Increased dietary intake of fish oil restored the activity of insulin receptor tyrosine kinase towards control values (Fickova et al. 1994).

Besides many studies on laboratory rodents, there are only few investigations in other animal models. One study (Behme 1996) has shown that insulin sensitivity in miniature pigs is enhanced by omega-3 provided even in the context of low-fat diet feeding, while omega-3 could also reduce abdominal fat deposition in birds (Newman et al. 2002).

Thus, even partial substitution of dietary lipids with EPA/DHA in either HC or HF diet is associated with a number of effects that can help to prevent the development of IR. Although the mechanism responsible for beneficial effects of omega-3 on insulin sensitivity in above mentioned animal models is not entirely clear, the common feature associated with omega-3 treatment primarily involves improved hepatic insulin sensitivity (Storlien et al. 1987, Neschen et al. 2007, Kuda et al. 2009, Jelenik et al. 2010) associated with reduced hepatic diacylglycerol accumulation (Neschen et al. 2007, Jelenik et al. 2010), reduced TAG deposition in various insulin-responsive tissues (Flachs et al. 2011, Rossmeisl et al. 2012) and low-grade inflammation of WAT (Kuda et al. 2009, Flachs et al. 2011, Rossmeisl et al. 2012).

Reversal of IR by omega-3 in animals

Some studies have shown acute effects of EPA/DHA administration in obese rodents (Shimura et al. 1997, Holness et al. 2004). Thus, acute (24-h) replacement of 7 % of dietary FA reversed insulin hypersecretion in vivo by rats fed HF diet and reverses the effects of HF feeding to enhance insulin secretion by perfused islets (Holness et al. 2004).

Relatively few studies have examined possible reversal of already established IR and obesity in response to omega-3, i.e. the metabolic condition relevant to T2D. In some studies, a model of IR induced by HC diet in the rat was used. Administration of omega-3 as fish oil normalized the levels of TAG, NEFA and glucose in plasma, TAG content and glycogen synthesis in the skeletal muscle, and glucose tolerance and whole-body insulin sensitivity (Lombardo et al. 1996, Pighin et al. 2003, Rossi et al. 2005). Furthermore, omega-3 completely normalized both fat storage and the pyruvate dehydrogenases activity within the β-cells as well as the insulin secretion patterns (Pighin et al. 2003). In contrast, another study with a similar design did not show any effect of omega-3 on established IR in rats (Podolin et al. 1998). We were able to demonstrate some of the beneficial effects of omega-3 administered as either TAG (Kuda et al. 2009, Rossmeisl et al. 2009, 2012) or phospholipid (Rossmeisl et al. 2012) on established obesity, glucose intolerance and dyslipidemia using the model of HF diet-fed C57BL/6J mice.

The results obtained using both HC diet-fed (Rossi et al. 2005) and HF diet-fed (Flachs et al. 2006, Jilkova et al. 2013; and see above) animals suggest that
modulation of secretion of adipokines by dietary omega-3 might play an essential role in the normalization of insulin sensitivity and adiposity in insulin-resistant models with diet-induced obesity.

Several studies (Linn et al. 1989, Churunratanakul et al. 1990, Giron et al. 1999, Ovide-Bordeaux and Gryenberg 2004) have also documented improvement of hyperglycemia in an experimental rat model of streptozotocin-induced type 1 diabetes, i.e. diabetes resulting primarily from decreased secretion of insulin.

Effects of omega-3 in rodent models of spontaneous diabetes mellitus or IR

Single administration of DHA decreased in a dose-dependent manner both plasma glucose and NEFA levels in diabetic KK-A\(^\text{y}\) mice (Shimura et al. 1997). Repeated administration of DHA reduced blood glucose, TAG and NEFA levels, decreased blood glucose during insulin tolerance test and reduced adiposity in KK-A\(^\text{y}\) mice (Shimura et al. 1997, Hun et al. 1999). In OLETF rats, an animal model of T2D, EPA supplementation lowered plasma TAG levels and abdominal fat accumulation and improved IR (Minami et al. 2002). In male WBN/Kob rats, a model of spontaneous diabetes mellitus, oral EPA treatment suppressed significantly and dose-dependently the incidence of diabetes (Nobukata et al. 2000). Dietary omega-3 have beneficial effects on both hypertension and glucose intolerance in spontaneously hypertensive (SHR) rats (Ajiro et al. 2000). In Goto-Kakizaki rat, an animal model of T2D, EPA improved glucose tolerance by directly increasing hepatic insulin sensitivity (Matsuura et al. 2004). In genetically obese ob/ob mice, fish oil-containing diet reduced the body weight gain and increased glucose-stimulated insulin secretion (GSIS), but also increased intercurrent mortality (Steerenberg et al. 2002).

Modulation of the incretin system by omega-3

T2D is characterized by the presence of IR and \(\beta\)-cell dysfunction. While the loss of \(\beta\)-cell function is pivotal for the T2D development, there are also defects in other endocrine systems that regulate glucose homeostasis (e.g. glucagon, incretins), which contribute to abnormal GSIS and other metabolic abnormalities. For instance, incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), apart from other functions (for review see Mudaliar and Henry 2012), augment GSIS after they are released from the gut in response to glucose and other nutrients absorption (i.e. incretin effect). This effect seems to be blunted in T2D subjects (Nauck et al. 1986), likely due to an impaired response to GIP and possibly also to GLP-1 (Højberg et al. 2009), or in some cases due to a reduced GLP-1 secretion (Nauck 2011). Thus, dietary omega-3 could exert some of their beneficial effects on IR and glucose homeostasis through the modulation of incretin hormones. In this regard, intracolonic administration (but not into other intestinal segments) of DHA and EPA in mice resulted in enhanced GLP-1 secretion, substantial insulin release and subsequent reductions in glycemia (Morishita et al. 2008). We have previously shown in mice that dietary DHA/EPA at the dose of 30 g/kg diet ameliorated whole-body IR induced by chronic HF feeding, mainly due to the modulation of hepatic insulin sensitivity (Kuda et al. 2009, Jelenik et al. 2010). Our unpublished data suggest that this level of DHA/EPA supplementation potentiates GLP-1 and insulin responses to a glucose load while normalizing abnormally elevated GIP levels observed in the control high-fat diet-fed mice. However, it is unclear whether a similar beneficial effect of omega-3 supplementation on the incretin system could be recapitulated in human subjects with IR and/or T2D.

Effects of omega-3 on insulin sensitivity and glucose homeostasis in humans

Most animal experiments document beneficial effects of omega-3 on insulin sensitivity and glucose metabolism even under conditions of established obesity and IR (see above). However, the situation in humans is more complicated, suggesting that omega-3’s effects may depend on disease progression, age of subjects and other variables. Therefore, for the purpose of this review, the effects of omega-3 on glucose homeostasis and related metabolic features will be examined separately within three major categories of subjects: healthy individuals, subjects with metabolic syndrome, and patients with T2D. Moreover, the effects in CVD patients will be also described.

Effects of omega-3 in healthy individuals

Cross-sectional studies documented that Greenlandic Inuits with a high dietary intake of marine fish had a lower incidence of atherosclerosis, type 1 diabetes and T2D (reviewed in Dyerberg 1986, Bjørregaard et al. 2000), while human population from fishing areas in Japan exhibited a relatively low incidence
of CVD, in association with lower plasma levels of cholesterol, LDL cholesterol (LDL-C), saturated FA, and omega-6 without changes in blood glucose (Nakamura et al. 2003). However, many of the subsequent observational studies gave inconsistent results with respect to the association between omega-3 intake and the incidence of either CVD or T2D (reviewed in Zheng et al. 2012).

In their seminal prospective cohort studies, Feskens et al. have shown that increased intake of marine fish could lower a relative risk of IGT in elderly individuals by 60 % (Feskens et al. 1991) and correlated negatively with glycemia 2 hours after glucose load (Feskens et al. 1995). Also some of the more recent prospective cohort studies observed a negative association between fish intake, namely of fatty fish (Patel et al. 2012, Zhang et al. 2013), and the risk of T2D, while some studies did show the opposite (Kaushik et al. 2009, Djousse et al. 2011b). A meta-analysis of the results of prospective-cohort studies performed by the group of Mozaffarian could not prove a significant association of either EPA+DHA or fish/seafood intake with the risk of T2D (Wu et al. 2012b). Importantly, however, in a prospective cohort study performed by the Mozaffarian’s group on generally healthy older adults in the US, in which circulating omega-3 levels (namely omega-3 index in plasma phospholipids) rather than dietary intake of omega-3 (assessed using dietary questionnaires in the other studies) were evaluated at the baseline year, circulating omega-3 were associated with lower CVD mortality (Cardiovascular Health Study; see Mozaffarian et al. 2013), lower risk of atrial fibrillation (Wu et al. 2012a), and possibly also with a lower risk of T2D (Djousse et al. 2011a). These results are in agreement with the findings of an even larger prospective cohort study concluded in 2013, which showed a long-term lower risk of T2D in older men with high plasma EPA+DHA levels (Virtanen et al. 2014), but they are not supported by all the studies with a similar design (reviewed in Djousse et al. 2011a).


The changes in glucose metabolism suggest that: (a) omega-3 might interfere with insulin secretion, which leads to a decrease in circulating insulin levels and a concomitant rise in blood glucose; and (b) the administration of omega-3 likely induces a switch in substrate metabolism, namely an increase in whole-body fat oxidation and a decrease in carbohydrate oxidation (Couet et al. 1997, Delarue et al. 2003). Thus, a 3-week-intervention with omega-3 in young subjects resulted in increased glucemia after a carbohydrate load, decrease in insulinemia, depression in carbohydrate oxidation, and increased glyceremia during exercise, while stimulating lipid oxidation (Delarue et al. 2003). These results suggest an inhibition of hepatic glucose production by a feedback mechanism (Delarue et al. 2003). In fact, the increase in non-oxidative glucose disposal documents increased insulin sensitivity of skeletal muscle, and suggests high metabolic flexibility to carbohydrates.

Thus, while the beneficial effects of omega-3 on blood lipids, especially TAG, in healthy individuals are evident, the same cannot be said about their effects on insulin sensitivity and glycemic control. A majority of association studies analysing dietary intake or plasma levels of omega-3, and metabolic parameters in various populations confirm that, in the long term, omega-3 have a beneficial effect. On the other hand, studies analysing the effect of acute administration of omega-3 on glycemic control in healthy individuals gave ambivalent results and the cause for these diverse effects is not entirely clear (see below).

Effects of omega-3 in subject with metabolic syndrome

Obesity and associated disorders included in metabolic syndrome, namely dyslipidemia, IGT and hypertension, predispose to both CVD and T2D. Regarding obesity itself, numerous clinical intervention studies were conducted showing either none or only
marginal weight-reducing effects of omega-3 intake (reviewed in Lorente-Cebrian et al. 2013). It seems logical that the additive weight-reducing effect was often detected when omega-3 intake was combined either with physical exercise (Warner et al. 1989, Hill et al. 2007) or reduced calorie intake (Mori et al. 1999, Krebs et al. 2006, Kunesova et al. 2006, Thorsdottir et al. 2007), also in accordance with our study in mice showing a strong prevention of dietary obesity in response to calorie restriction combined with omega-3 intake (Flachs et al. 2011; and see above). Interestingly, several association studies in humans also document a negative correlation between omega-3 content in WAT (Pietiläinen et al. 2007) or plasma lipids (Micallef et al. 2009) and obesity.

While hypertriglyceridemia supports the development of atherosclerosis and CVD, lipid-lowering effects of omega-3 consistently observed in metabolic syndrome patients (reviewed in Jeppesen et al. 2013) may represent one of the key factors underlying the beneficial role of omega-3 in both primary (see above) and possibly also secondary (see below) prevention of CVD. A meta-analysis of studies in patients with metabolic syndrome or T2D (MacLean et al. 2004), published in 2004, has shown, that although omega-3 significantly lowered plasma TAG compared to placebo, omega-3 affected neither total cholesterol levels, HDL-cholesterol, LDL-C, HbA1c, nor fasting glycemria.

Profound changes in glucose homeostasis represented by IGT and IR, which could eventually lead to T2D, represent the characteristic feature of metabolic syndrome. Several intervention trials performed mostly in obese children (Lopez-Alarcon et al. 2011, Dangardt et al. 2012, Juarez-Lopez et al. 2013) or in young overweight or obese individuals (without T2D) demonstrated an amelioration of IGT and IR (Ramel et al. 2008), independently from changes in body weight (Ramel et al. 2008, Dangardt et al. 2012). Similar studies in adult patients showed mixed results (reviewed in Lorente-Cebrian et al. 2013). A study, in which the effect of fish oil was studied in patients with IGT using hyperinsulinemic clamp, documented beneficial effects of omega-3 on insulin sensitivity evaluated at the lower but not higher insulin concentrations (Fasching et al. 1991).

The beneficial effects on metabolic syndrome features are associated, and could be explained in part, by the anti-inflammatory effects of omega-3 (see above). In human subjects with metabolic syndrome, the anti-inflammatory influence of omega-3 is well documented both at the systemic level (Calder and Yaqoob 2010, Itariu et al. 2012, 2013) as well as in adipose tissue (Itariu et al. 2012, Neuhofer et al. 2013).

The above data indicate that omega-3 could ameliorate various features of metabolic syndrome including the impairment of glucose homeostasis in prediabetic subjects, which could be masked or augmented by many variables. In this respect, it is no surprise that cross-sectional studies on the effects of omega-3 on metabolic syndrome as a whole, while neglecting important variables and possible effects on specific features of metabolic syndrome, gave negative results (e.g. Lai et al. 2013).

Effects of omega-3 in patients with T2D

Motivated by the initial discovery regarding the prevention of IR by omega-3 supplementation in rats fed HF diet (Storlien et al. 1987, 1991) and by the results of the early epidemiological studies showing a lower risk of T2D and CVD in some populations (see above), numerous intervention trials focusing on the effect of omega-3 on glucose homeostasis in diabetic patients have been conducted. The initial results obtained in small patient cohorts in the late 80’s and early 90’s (using less concentrated omega-3 products or natural fish oils) were not encouraging, since they showed either no (Kasim et al. 1988) or detrimental (Glauber et al. 1988, Borkman et al. 1989, Hendra et al. 1990, Vessby and Boberg 1990) effects on glucose homeostasis. Fasting blood glucose was elevated (Glauber et al. 1988, Borkman et al. 1989, Hendra et al. 1990, Vessby and Boberg 1990) and hepatic glucose production increased (Glauber et al. 1988), while glucose disposal rate and glucose tolerance were either decreased (Vessby and Boberg 1990) or unchanged (Glauber et al. 1988). Although fasting insulin levels were unchanged, glucose-stimulated insulin levels were lowered by omega-3 supplementation (Glauber et al. 1988).

As reviewed in detail previously (Mostad et al. 2006), subsequent RCTs in patients with T2D could not find better insulin sensitivity after omega-3 supplementation, while some of the studies even revealed decreased insulin secretion in omega-3-treated subjects. Nevertheless, most of the subsequent studies showed no change in glycemic control (i.e. based on fasting blood glucose or HbA1c levels) after omega-3 supplementation (Fasching et al. 1991, Pelikanova et al. 1993, Axelrod et al. 1994, McGrath et al. 1996, McManus et al. 1996, Goh et al. 1997, Sirtori et al. 1997, Kesavulu et al. 2002, Bosch et al. 2012), while proving hypotriglyceridemic
effects of omega-3. A very recent RCT in T2D patients revealed a positive effect of purified EPA-based supplement on glucose homeostasis (Sarbouloki et al. 2013).

A deterioration of insulin sensitivity in obesity could reflect several different mechanisms, including glucotoxicity and lipotoxicity, while it is marked by an impaired metabolic flexibility (see the section Key mechanisms underlying deterioration of insulin sensitivity above). Various animal studies document increased lipid catabolism by omega-3, which could be involved in counteracting lipotoxic damage of insulin signaling (see above). In contrast to a large number of studies examining the effects of omega-3 on glucose homeostasis and insulin sensitivity in T2D patients, studies focused on the effects of omega-3 on metabolic flexibility in T2D patients, typically assessed using indirect calorimetry, are scarce. In one RCT on T2D patients (Mostad et al. 2006), indirect calorimetry in fasted state demonstrated temporarily increased glucose utilization after 1 week of omega-3 treatment, after which (after 9 weeks of treatment) it was decreased with a concomitant increase in lipid utilization. Glucose utilization evaluated during the indirect calorimetry by using hyperinsulinemic euglycemic clamp, a conventional measure of insulin sensitivity, was also decreased. Although indirect calorimetry was also performed at the end of the clamp study, the potential effect of omega-3 on metabolic flexibility is difficult to assess from the available data. In another RCT performed by the same group, in which the acute effects of omega-3 administered as lipid infusion were tested in patients with T2D, no change in insulin sensitivity was observed using hyperinsulinemic euglycemic clamp, while indirect calorimetry suggested a marginal improvement of metabolic flexibility (Mostad et al. 2009).

It is to be inferred that the interpretation of the results of the conventional measurements regarding the effects of omega-3 on glucose homeostasis and insulin sensitivity are complicated by the time-dependent changes in the capacity to oxidize carbohydrate and lipid fuels in response to omega-3. Nevertheless, the available data suggest that omega-3 have a neutral/marginal effect on glycemic control in diabetic patients, while exerting beneficial hypolipidemic effects.

**Effects of omega-3 in patients with CVD**

Diabetes imposes the risk of CVD morbidity and mortality, which in turn represent the major adverse events in T2D patients (Seshasai et al. 2011). Reflecting the positive results of several cross-sectional and prospective cohort studies with respect to prevention of CVD and T2D by omega-3 (see above), several major RCTs were focused on the effect of omega-3 in subjects with a history of myocardial infarction or other CVD risk factors. In spite of positive data coming from the older RCTs showing beneficial effects in the secondary prevention of CVD (especially the influential GISSI trial; Marchioli 1999), in the majority of the recent RCTs of a similar design (Kromhout et al. 2010, Rauch et al. 2010, Roncaglioni et al. 2013) omega-3 did not significantly reduce CVD-related morbidity and mortality. This was also true for the ORIGIN trial performed on 12,536 people (mean age of 63.5 years and median follow-up of 6.2 years) with IFG, IGT, or T2D, who were also at risk of CVD events (Bosch et al. 2012, Gerstein et al. 2012). In this trial with 2-by-2 factorial design, in which the effects of omega-3 (1 g EPA+DHA ethyl ester daily) and insulin glargine were tested, neither omega-3 nor glargine reduced the risk of CVD events, but omega-3 exerted a hypotriglyceridemic effect (Bosch et al. 2012) while glargine reduced new-onset diabetes, increased hypoglycemia and increased weight (Gerstein et al. 2012).

The reasons for the contrasting results regarding omega-3’s effects on CVD events observed in the older versus more recent RCTs are not clear (see below); that unknown variables could modulate the effects of omega-3 is also documented by the contrasting results of two recent meta-analyses (Kwak et al. 2012, Casula et al. 2013). Interestingly, secondary analysis of the results of one of the RCTs performed in patients with previous myocardial infarction, showing negative results with respect to the secondary prevention of CVD by omega-3 in the whole patients’ cohort (Kromhout et al. 2010), suggested protective effects in the subgroup of patients with T2D (Kromhout et al. 2011). Also in the JELIS trial performed on 18,645 hypercholesterolemic patients in Japan (i.e. the population with a high fish intake), encompassing either normoglycemic patients or patients with IGT or T2D, the treatment with EPA resulted in a reduced incidence of CVD with stronger effects in the prediabetic than in diabetic patients (Oikawa et al. 2009). Unfortunately, whether omega-3 could reduce new-onset diabetes was not evaluated neither the ORIGIN nor in the JELIS trial.

The lack of health benefits of omega-3 administration in some of the RCTs was interpreted in
a way that the effect of omega-3 could be too weak to be manifested against the background of intensive modern preventive therapy. For instance, it has been suggested that some effects of statin drugs could counteract the CVD health benefits of omega-3 (de Lorgeril et al. 2013). Although attractive, this hypothesis does not seem to be the main explanation, reflecting also the observed additional benefits of the combination therapy using omega-3 and statins on dyslipidemia in T2D patients (de Lorgeril et al. 2013). A recent retrospective matched-control study on patients after myocardial infarction with or without T2D documented that omega-3 supplementation was associated with a 22% reduction of all-cause mortality, independent of other CVD-risk modifying treatments (Poole et al. 2013); in this study, 2,466 eligible subjects were exposed to omega-3 and each of them was matched to 4 other patients that had been without omega-3. Importantly, this „real-world evaluation of clinical practice“ complements RCTs by demonstrating that a treatment with licenced omega-3 was associated with reduced all-cause mortality only when initiated within 90 days and preferentially within 14 days after the myocardial infarction (Poole et al. 2013), i.e. under the conditions met by only one of the recent RCTs (Rauch et al. 2010). However, as stated by the authors of this trial, the data do not allow a final answer on the potential CVD-related benefits of omega-3, since the study was statistically underpowered (Rauch et al. 2010). None of the RCTs was designed to uncover potential interactions between omega-3 and glucose-lowering drugs.

Thus, in spite of the tremendous efforts spent in the RCTs above, definitive conclusions regarding the effects of omega-3 in the secondary prevention of CVD, or in the development of new-onset diabetes in high-risk persons cannot be made.

Conclusions

While the results of both animal and human studies document beneficial effects of omega-3 with respect to prevention/normalization of hypertriglyceridemia and amelioration of systemic low-grade inflammation as well as tissue inflammatory changes, which are accompanying obesity, the results are inconsistent regarding the effects of omega-3 on glucose homeostasis and insulin sensitivity in animal models and in human subjects. While in the animal studies, namely in dietary obese mice, omega-3 are consistently shown to prevent IR and to reverse already established IR, the situation in human subjects is more complex.

Most of the cross-sectional studies in healthy populations, as well as intervention studies in people with metabolic syndrome, document that omega-3 could prevent development of T2D and ameliorate disorders of glucose homeostasis. Such conclusion is also supported by a prospective cohort study in generally healthy older adults, in which omega-3 levels in circulation rather than dietary omega-3 intake were evaluated. Results of the majority of RCTs performed in patients with T2D suggest that omega-3 have none or marginal effects on metabolic control, while effectively reducing hypertriglyceridemia in these patients. In spite of this beneficial hypolipidemic action of omega-3, the results of several recent RCTs mostly suggest no effect of omega-3 in secondary prevention of CVD, but confounding factors could be involved and thus no definitive conclusion could be made. Potential effects of omega-3 on a risk of new-onset diabetes in prediabetic subjects remain to be characterized.

Regarding the effects of omega-3 on glucose homeostasis and insulin sensitivity, many factors may underlie the interspecies differences as well as the inconsistent outcomes of the human studies. Some mechanisms may differ among the species, namely those involving hepatic action of omega-3. While the animal studies are much easier with respect to elimination of many confounding effects (genetic background including the effects of various allelic forms of critical genes, diet composition, adherence to the treatment, age, environment, etc.), the human studies are inherently much more heterogeneous, reflecting not only the variables that are controlled for in the animal studies (see above), but also with respect to the interactions with other pharmaceuticals used for the treatment of patients. Factors modulating bioavailability of omega-3, like their lipid form and/or the presence of other nutrients, may be critical. It is conceivable that also in human subjects, the effects of omega-3 will be better established when the assessment of omega-3 index is taken into account. It will be also helpful to control for the effects of more critical variables in well focused studies and using combinations of appropriate phenotyping approaches for specific end points.

In spite of the negative results observed in many clinical studies, namely EPA and DHA have been shown to exert numerous beneficial effects on health and should be increasingly used in the prevention of T2D, CVD and
other diseases that are frequently associated with obesity and inflammation. Current guidelines regarding omega-3 intake in general population should be followed. The use of omega-3 and changes in lifestyle in the therapy of major diseases including T2D should be further explored, namely with respect to their combination with pharmaceuticals.

**Conflict of Interest**
There is no conflict of interest.

**Acknowledgements**
Supported by the Ministry of Health of the Czech Republic (NT13763-4) and RVO: 67985823.

**Abbreviations**
AA, arachidonic acid (20:4n-6); ALA, α-linolenic acid (18:3n-3); BCAA, branched-chain amino acids; CVD, cardiovascular disease; DHA, docosahexaenoic acid (22:6n-3); FA, fatty acids; HbA1c, glycated hemoglobin; HC, high carbohydrate diet; HDL, high-density lipoprotein; HF, high-fat diet; EPA, eicosapentaenoic acid (20:5n-3); GIP, glucose-dependent insulinogetic polypeptide; GLP-1, glucagon-like peptide-1; GSIS, glucose-stimulated insulin secretion; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; IR, insulin resistance; LA, linoleic acid (18:2n-6); LC-PUFA, long-chain polyunsaturated fatty acids; LDL, low-density lipoprotein; LDL-C, LDL cholesterol; NEFA, non-esterified fatty acids; n-6/n-3, ratio between n-6 and n-3 polyunsaturated fatty acids in the diet; omega-3, long-chain polyunsaturated fatty acids n-3 series; OGTT, oral glucose tolerance test; PPAR, peroxisome proliferator-activated receptor; PUFA, polyunsaturated fatty acids; RCT, randomized clinical trial; T2D, type 2 diabetes; TAG, triacylglycerols; TAG/FA, futile substrate cycle based on hydrolysis of triacylglycerols and re-esterification of fatty acids; TZD, thiazolidinediones; VLDL, very-low-density lipoprotein.

**References**


